The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Honoraria - ARIAD; AstraZeneca; Guardant Health; Pfizer; Spectrum Pharmaceuticals; Takeda; Trovagene
Consulting or Advisory Role - AstraZeneca; GreenPeptide; Ignyta; OncoMed; Pfizer; Trovagene
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - ARIAD; Guardant Health; Ignyta
 
Gregory J. Riely
Consulting or Advisory Role - Genentech
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Lilly; Merck; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Zofia Piotrowska
Consulting or Advisory Role - Abbvie; ARIAD/Takeda; AstraZeneca; Boehringer Ingelheim; Guardant Health; Novartis; Superdimension
Research Funding - ARIAD/Takeda (Inst); Guardant Health (Inst); Novartis (Inst)
 
Daniel Botelho Costa
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca
 
Joel W. Neal
Consulting or Advisory Role - ARIAD/Takeda; AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - ARIAD/Takeda; ArQule; Boehringer Ingelheim; Exelixis; Genentech/Roche; Merck; Nektar; Novartis
 
Steven Zhang
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
William Reichmann
No Relationships to Disclose
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Shuanglian Li
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals
Consulting or Advisory Role - Araxes Pharma; ARIAD; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Pfizer; Roche/Genentech
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention